“The Tafenoquine for Babesiosis Expanded Access clinical study may strengthen that hope in a patient population that has few treatment options today. We are pleased to be leading the way in ...

“The promise shown by tafenoquine in treating relapsing babesiosis can certainly give patients and physicians reason for hope and optimism,” said Geoff Dow, PhD, chief executive officer of 60 ...

announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine, marketed as ARAKODA®, for treating ...

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in ...

However, the hypnozoiticidal efficacy of current drugs like primaquine and tafenoquine cannot be directly assessed due to the undetectable nature of hypnozoites. Researchers conducted a retrospective ...

(SXTPW), a pharmaceutical company specializing in infectious disease treatments, on Wednesday announced the expansion of its clinical trial for tafenoquine, a potential treatment for babesiosis ...

A clinical case series recently published in Clinical Infectious Diseases showed that tafenoquine exhibited an 80 percent cure rate in five high-risk patients with persistent, relapsing babesiosis ...

60 Degrees Pharmaceuticals (SXTP) announced that the first patient has been enrolled in NCT06478641, an expanded access clinical study intended to confirm the activity of tafenoquine in treating ...